Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 203-209

  Fukuchi, Takeo ^a   Wakai, Kimiko ^a   Suda, Kieko ^a   Nakatsue, Tomoko ^a   Sawada, Hideko ^a   Hara, Hiroaki ^a   Ueda, Jun ^a   Tanaka, Takayuki ^a   Yamada, Akiko ^a   Abe, Haruki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

AD classification; Eye drops; Glaucoma; Keratoepitheliopathy; Medications

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; CORNEA DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; KERATOEPITHELIOPATHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEOVASCULAR GLAUCOMA; NORMAL TENSION GLAUCOMA; OPEN ANGLE GLAUCOMA; PSEUDOEXFOLIATION GLAUCOMA; PUNCTATE KERATITIS; SLIT LAMP; UVEITIS;

EID: 77953458840     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Article

References (35)

1. Alm A, Stjernschantz J. Effect on intraocular pressure and side effect of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology. 1995;102(12):1743-1752.
2. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103(1):126-137.
3. Camras CB. The United States latanoprost study group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology. 1996;103(1):138-147.
4. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: A comparison of safety and efficacy. J Glaucoma. 2007;16(1):98-103.
5. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAC-free solution. J Glaucoma. 2008:17(3);217-222.
6. Donohue EK, Wilensky JT. Trusopt. A topical carbonic anhydrase inhibitor. J Glaucoma. 1996;5(1):68-74.
7. Araie M, Kitazawa Y, Azuma I, et al. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents. J Ocul Pharmacol Ther. 2003;19(6):517-525.
8. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. The Brinzolamide Primary Therapy Study. Ophthalmology. 1998;126(3):400-408.
9. Konstas AG, Mantziris DA, Maltezos A, et al. Comparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucoma. Acta Ophthalmol Scand. 1999;77(5):541-543.
10. Baudouin C, de Lunard C. Short term comparative study of topical 2% carteolol with or without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82(1):39-42.
11. Piesella PJ, Fillacier K, Elena PP, et al. Comparison of the effects on preserved and unpreserved formulations of timolol on the cornea surface of albino rabbits. Ophthalmic Res. 2000;32(1):3-8.
12. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preserved-free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423.
13. Edelhauser HF, Ubels J. The cornea and the sclera. In: Kaufman PL, Alm A, editors. Adler's Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2003:47-114.
14. Pfister RR, Burstein NL. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: A scanning electron microscope study. Invest Ophthalmol Vis Sci. 1976;15(4):246-259.
15. Burstein NL. Corneal toxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25(1):15-30.
16. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on grows and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40(3):619-630.
17. Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. Cornea. 2006;25(10):1133-1138.
18. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99(7):1082-1088.
19. Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol. 1993;77(9):590-596.
20. van Buskirk EM. Corneal anesthesia after timolol malate therapy. Am J Ophthalmol. 1979;88(4):739-743.
21. Wilson RP, Spaeth GL, Poryzees E. The place of timolol in the practice of ophthalmology. Ophthalmology. 1980;87(5):451-454.
22. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol. 1990;74(7):409-412.
23. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12(6):480-485.
24. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12(6):486-490.
25. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20(1):85-94.
26. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46(7):2444-2450.
27. Ayaki M, Noda Y, Yaguchi S, et al. Cytotoxicity of antiglaucoma ophthalmic solutions for human corneal endothelial cells. J Jap Ophthalmol Soc. 2009;113(5):576-582.
28. Leung EW, Mediros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-355.
29. Lass JH, Khosrof SA, Laurence JK. A double masked, randomized, 1-year study comparing the corneal effect of dorzolamide, timolol, and betaxolol. Arch Ophthalmol. 1999;116(8):1003-1010.
30. Reidy JJ, Zarzour J, Thompson HW, Beuerman RW. Effect of topical beta blocker on corneal epithelial wound healing in the rabbit. Br J Ophthalmol. 1994;78(5):377-380.
31. Miyata K, Amano S, Sawa M, Nishida T. A novel grading methods for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol. 2003;121(11): 1537-1539.
32. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. 2008. Available from: http://www.eugs.org/eng/EGS_guidelines.asp. Accessed Feb 28, 2010.
33. Japan Glaucoma Society. Guidelines for Glaucoma. Tokyo, Japan: Japan Glaucoma Society; 2002.
34. Lucarelli MJ, Dart DA, Cook BE, Lemke BN. The lacrimal system. In: Kaufman PL, Alm A, editors. Adler's Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2002:30-43.
35. Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology. 2006;113(8):1333-1339.